Immune monitoring using the predictive power of immune profiles
Dietz, A, Gustafson, M.P, Lin, Y, LaPlant, B.R, Liwski, C.J, Maas, M.L, League, S.C, Bauer, P.R, Abraham, R.S, Tollefson, M.K, Kwon, E.D, Gastineau, D.A
Published in Cytotherapy (Oxford, England) (01.04.2013)
Published in Cytotherapy (Oxford, England) (01.04.2013)
Get full text
Journal Article
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
Witzig, T E, Reeder, C B, LaPlant, B R, Gupta, M, Johnston, P B, Micallef, I N, Porrata, L F, Ansell, S M, Colgan, J P, Jacobsen, E D, Ghobrial, I M, Habermann, T M
Published in Leukemia (01.02.2011)
Published in Leukemia (01.02.2011)
Get full text
Journal Article
Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane®) in combination with gemcitabine in patients with metastatic breast cancer (N0531)
Roy, V., LaPlant, B. R., Gross, G. G., Bane, C. L., Palmieri, F. M.
Published in Annals of oncology (01.03.2009)
Published in Annals of oncology (01.03.2009)
Get full text
Journal Article
Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma
Inwards, D.J., Fishkin, P.A., LaPlant, B.R., Drake, M.T., Kurtin, P.J., Nikcevich, D.A., Wender, D.B., Lair, B.S., Witzig, T.E.
Published in Annals of oncology (01.02.2019)
Published in Annals of oncology (01.02.2019)
Get full text
Journal Article
Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma
Inwards, D.J., Fishkin, P.A., LaPlant, B.R., Drake, M.T., Kurtin, P.J., Nikcevich, D.A., Wender, D.B., Lair, B.S., Witzig, T.E.
Published in Annals of oncology (01.10.2014)
Published in Annals of oncology (01.10.2014)
Get full text
Journal Article